keyword
MENU ▼
Read by QxMD icon Read
search

Dysport

keyword
https://www.readbyqxmd.com/read/29230798/botulinum-toxin-type-a-therapy-for-cervical-dystonia
#1
REVIEW
Mafalda Castelão, Raquel E Marques, Gonçalo S Duarte, Filipe B Rodrigues, Joaquim Ferreira, Cristina Sampaio, Austen P Moore, João Costa
BACKGROUND: This is an update of a Cochrane Review first published in 2005. Cervical dystonia is the most common form of focal dystonia and is a highly disabling movement disorder characterised by involuntary, usually painful, head posturing. Currently, botulinum toxin type A (BtA) is considered the first line therapy for this condition. OBJECTIVES: To compare the efficacy, safety, and tolerability of botulinum toxin type A (BtA) versus placebo in people with cervical dystonia...
December 12, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29229221/intravesical-electromotive-botulinum-toxin-type-a-administration-for-management-of-urinary-incontinence-secondary-to-neuropathic-detrusor-overactivity-in-children-long-term-follow-up
#2
Seyedeh-Sanam Ladi-Seyedian, Lida Sharifi-Rad, Abdol-Mohammad Kajbafzadeh
OBJECTIVES: To investigate the long-term efficacy and success rate of intravesical electromotive botulinum toxin type A (BoNTA) "Dysport®" administration in myelomeningocele (MMC) patients who had urinary incontinence due to neuropathic detrusor overactivity (NDO). METHODS: Twenty four MMC patients (mean age: 9± 3.6 years, range: 3-16) were included in the study and followed up for six years. Using an electrode bladder catheter, 10 IU/kg of Dysport® (BoNTA) was inserted into the bladder for electromotive drug administration (EMDA) without anesthesia on outpatient basis...
December 8, 2017: Urology
https://www.readbyqxmd.com/read/29093068/efficacy-and-safety-of-abobotulinumtoxina-in-spastic-lower-limb-randomized-trial-and-extension
#3
Jean-Michel Gracies, Alberto Esquenazi, Allison Brashear, Marta Banach, Serdar Kocer, Robert Jech, Svetlana Khatkova, Ján Benetin, Michele Vecchio, Peter McAllister, Jan Ilkowski, Stanislaw Ochudlo, France Catus, Anne Sophie Grandoulier, Claire Vilain, Philippe Picaut
OBJECTIVE: To demonstrate single abobotulinumtoxinA injection efficacy in lower limb vs placebo for adults with chronic hemiparesis and assess long-term safety and efficacy of repeated injections. METHODS: In a multicenter, double-blind, randomized, placebo-controlled, single-cycle study followed by a 1-year open-label, multiple-cycle extension, adults ≥6 months after stroke/brain injury received one lower limb injection (abobotulinumtoxinA 1,000 U, abobotulinumtoxinA 1,500 U, placebo) followed by ≤4 open-label cycles (1,000, 1,500 U) at ≥12-week intervals...
November 1, 2017: Neurology
https://www.readbyqxmd.com/read/29053134/-conversion-ratio-between-different-botulinum-neuroprotein-product-in-neurological-practice
#4
O R Orlova, S L Timerbaeva, S E Khatkova, E V Kostenko, D A Krasavina, D V Zakharov
Despite nearly 30 years of experience in the application of botulinum toxin type A (BTA) in clinical practice, many fundamental questions of therapy remain valid. There are 5 botulinum toxin type A used for neurological indications in the Russian Federation in 2017. They contain different number of active neuroprotein (150 kDa) in a therapeutic dose of the drug that may have a potential impact on the efficacy and duration of action. The current SmPC of each BTA stated that the unit of activity is unique and can not be compared with any other BTA...
2017: Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova
https://www.readbyqxmd.com/read/29040367/forehead-lift-using-botulinum-toxin
#5
Sarit Cohen, Ofir Artzi, Lior Heller
Background: The principle of dynamic muscular activity affecting eyebrow height and shape is well known. We postulate that similarly, dynamics of the fronto-galea-occipital muscles affect forehead height. Objectives: To present a forehead lift technique using Botulinum toxin injection and evaluate its clinical efficacy and safety. Methods: Twenty-nine female patients comprised the study group. Forty units of prepared abobutolinumtoxinA (Dysport, 10 U/0...
October 10, 2017: Aesthetic Surgery Journal
https://www.readbyqxmd.com/read/28915291/cosmetic-practitioners-take-huge-risks-purchasing-and-administering-illegal-botulinum-toxin-drug-products
#6
Sheldon Bradshaw
In their article "Importing Injectables" in the September 2014 issue of the Journal of Drugs in Dermatology, Dr. Kenneth Beer and Karen Rothschild highlighted the possible harm to patients and practitioners from the use of unapproved botulinum toxin products - eg, Botox, Dysport, Xeomin, and Myobloc - and other cosmetic prescription drug products purchased from foreign or unlicensed suppliers.1 In the intervening years, the accuracy of their critique has been repeatedly demonstrated, as the dangers to patients' health, as well as to cosmetic practitioners' liberty, has only increased...
September 1, 2017: Journal of Drugs in Dermatology: JDD
https://www.readbyqxmd.com/read/28904941/is-there-any-relationship-between-bladder-trabeculation-and-efficacy-and-safety-of-intravesical-botulinum-toxin-a-injection-in-refractory-idiopathic-overactive-bladder-women
#7
Mahtab Zargham, Shideh Abedi, Farshid Alizadeh, Mohamad Hatef Khorami, Mehrdad Mohamadi, Faranak Bahrami, Farzaneh Sharifiaghdas, Hamid Mazdak
BACKGROUND: Intradetrusor injection of botulinum toxin A (BTX-A) might serve as a minimally invasive substitute in patients with refractory idiopathic overactive bladder (RIOAB). The aim of this study was to evaluate the clinical outcomes related to two different doses of abo-BTX-A (AboBTX-A) in patients with RIOAB. MATERIALS AND METHODS: This prospective clinical trial was performed on 55 women with RIOAB. After determination of trabeculation grade, 300 (no or mild) or 500 (moderate or severe) unit of AboBTX-A (Dysport) was intravesicaly injected...
2017: Advanced Biomedical Research
https://www.readbyqxmd.com/read/28669425/-treatment-of-hailey-hailey-disease-with-botulinic-toxin-a-retrospective-study-of-8-cases
#8
L Dousset, A Pham-Ledard, M-S Doutre, M Beylot-Barry, O Cogrel
BACKGROUND: Hailey-Hailey disease (HHD) is characterised by episodes of weeping erythematous lesions, particularly in areas subject to friction or maceration. Treatment is complex. The value of botulinum toxin has been demonstrated in several studies and in individual cases. AIM: To report clinical and progressive data for 8 patients treated for HHD with injections of botulinum toxin A (BTX-A), following the failure of several other therapeutic approaches. PATIENTS AND METHODS: Eight patients (three males and five females), of median age 52...
October 2017: Annales de Dermatologie et de Vénéréologie
https://www.readbyqxmd.com/read/28657917/patient-registry-of-spasticity-care-world-data-analysis-based-on-physician-experience
#9
Alberto Esquenazi, Stella Lee, Nathaniel Mayer, Roser Garreta, Atul Patel, Elie Elovic, Stephen Koelbel, Gerard Francisco, Iris Reuter
OBJECTIVE: The aim of the study was to report physician experience-based "real-world" treatment patterns with botulinum toxin type A in patients with stroke and traumatic brain injury. DESIGN: A prospective, multicenter, international observational registry design was used. RESULTS: Six hundred twenty-seven participants with stroke and 132 participants with traumatic brain injury were assessed and treated by 17 more experienced physicians and 12 less experienced physicians...
December 2017: American Journal of Physical Medicine & Rehabilitation
https://www.readbyqxmd.com/read/28639368/botulinum-toxin-state-of-the-art
#10
REVIEW
Joseph Jankovic
Botulinun neurotoxin (BoNT) has emerged as one of the most multipurpose therapeutic agents in modern medicine with more clinical applications than any other drug currently on the market. Initially developed in the treatment of strabismus and neurologic movement disorders, the use of botulinun neurotoxin has been expanding during the past 3 decades to include the treatment of a variety of ophthalmologic, gastrointestinal, urologic, orthopedic, dermatologic, dental, secretory, painful, cosmetic, and other conditions...
August 2017: Movement Disorders: Official Journal of the Movement Disorder Society
https://www.readbyqxmd.com/read/28634000/dose-dependent-effects-of-abobotulinumtoxina-dysport-on-spasticity-and-active-movements-in-adults-with-upper-limb-spasticity-secondary-analysis-of-a-phase-3-study
#11
Michael W O'Dell, Allison Brashear, Robert Jech, Thierry Lejeune, Philippe Marque, Djamel Bensmail, Ziyad Ayyoub, David M Simpson, Magali Volteau, Claire Vilain, Philippe Picaut, Jean Michel Gracies
BACKGROUND: AbobotulinumtoxinA has beneficial effects on spasticity and active movements in hemiparetic adults with upper limb spasticity (ULS). However, evidence-based information on optimal dosing for clinical use is limited. OBJECTIVE: To describe joint-specific dose effects of abobotulinumtoxinA in adults with ULS. DESIGN: Secondary analysis of a phase 3 study (NCT01313299). SETTING: Multicenter, international, double-blind, placebo-controlled clinical trial...
June 19, 2017: PM & R: the Journal of Injury, Function, and Rehabilitation
https://www.readbyqxmd.com/read/28625615/efficacy-and-safety-of-abobotulinumtoxina-dysport-for-the-treatment-of-hemiparesis-in-adults-with-upper-limb-spasticity-previously-treated-with-botulinum-toxin-subanalysis-from-a-phase-3-randomized-controlled-trial
#12
Christina Marciniak, Peter McAllister, Heather Walker, Allison Brashear, Steven Edgley, Thierry Deltombe, Svetlana Khatkova, Marta Banach, Fatma Gul, Claire Vilain, Philippe Picaut, Anne-Sophie Grandoulier, Jean-Michel Gracies
OBJECTIVE: To assess the efficacy and safety of abobotulinumtoxinA in adults with upper limb spasticity previously treated with botulinum toxin A (BoNT-A). DESIGN: A post hoc analysis from a Phase 3, prospective, double-blind, randomized, placebo-controlled study (NCT01313299). SETTING: A total of 34 neurology or rehabilitation clinics in 9 countries. PARTICIPANTS: Adults aged 18-80 years with hemiparesis, ≥6 months after stroke or traumatic brain injury...
June 16, 2017: PM & R: the Journal of Injury, Function, and Rehabilitation
https://www.readbyqxmd.com/read/28623614/abobotulinumtoxina-a-review-in-pediatric-lower-limb-spasticity
#13
REVIEW
Yahiya Y Syed
AbobotulinumtoxinA (Dysport(®)) is currently the only botulinum toxin A formulation approved by the US FDA for the treatment of lower limb spasticity in pediatric patients aged ≥2 years. Intramuscular abobotulinumtoxinA was approved based on the results of a pivotal phase 3 trial in children with lower limb spasticity due to cerebral palsy. In this trial, a single treatment cycle with abobotulinumtoxinA 10-15 U/kg/leg injected into the gastrocnemius and soleus muscles significantly improved ankle plantar flexor muscle tone (primary endpoint), with abobotulinumtoxinA recipients showing a significant response to treatment relative to placebo...
August 2017: Paediatric Drugs
https://www.readbyqxmd.com/read/28590525/effects-of-repeated-abobotulinumtoxina-injections-in-upper-limb-spasticity
#14
Jean-Michel Gracies, Michael O'Dell, Michele Vecchio, Peter Hedera, Serdar Kocer, Monika Rudzinska-Bar, Bruce Rubin, Sofiya L Timerbaeva, Anna Lusakowska, François Constant Boyer, Anne-Sophie Grandoulier, Claire Vilain, Philippe Picaut
INTRODUCTION: The efficacy of single injections of abobotulinumtoxinA (Dysport) is established in adults with upper limb spasticity. In this study we assessed the effects of repeated injections of abobotulinumtoxinA over 1 year. METHODS: Patients (n = 258, safety population) received 500 U, 1,000 U, or 1,500 U (1,500-U dose included 500-U shoulder injections) for up to 4 or 5 treatment cycles. Assessments included treatment-emergent adverse events (TEAEs), muscle tone, passive and active range of motion (XV1, XA ), angle of catch (XV3 ), Disability Assessment Scale (DAS) score, Modified Frenchay Scale (MFS) score, and Physician Global Assessment (PGA) score...
June 7, 2017: Muscle & Nerve
https://www.readbyqxmd.com/read/28465830/economics-of-botulinum-toxin-therapy-influence-of-the-abobotulinumtoxina-package-size-on-the-costs-of-botulinum-toxin-therapy
#15
Dirk Dressler, Fereshte Adib Saberi
BACKGROUND: AbobotulinumtoxinA (Dysport®) was distributed for many years in vials containing 500MU (D500). Recently a new 300MU vial (D300) was additionally introduced (introduction). We wanted to explore whether more differentiated package sizes allow for more economic use of Dysport® in a large neurological botulinum toxin (BT) outpatient clinic. METHODS: The study followed a retrospective chart review design based on our digital BT therapy data bank. All patients receiving Dysport® exclusively in a constant dose during the observation period (introduction ± 7 months) were included...
2017: Journal of Clinical Movement Disorders
https://www.readbyqxmd.com/read/28431196/switch-to-abobotulinum-toxin-a-may-be-useful-in-the-treatment-of-neurogenic-detrusor-overactivity-when-intradetrusor-injections-of-onabotulinum-toxin-a-failed
#16
Florie Bottet, Benoit Peyronnet, Romain Boissier, Bénédicte Reiss, Jean G Previnaire, Andrea Manunta, Jacques Kerdraon, Alain Ruffion, Loïc Lenormand, Brigitte Perrouin Verbe, Sarah Gaillet, Xavier Gamé, Gilles Karsenty
AIMS: To assess the outcomes of switching to a different brand of botulinum toxin A (BTA, from Botox® to Dysport®) in case of failure of intradetrusor injections (IDI) of Botox® in the treatment of neurogenic detrusor overactivity (NDO). METHODS: The charts of all patients who underwent a switch to IDI of Dysport® after failure of an IDI of Botox® at six departments of neurourology were retrospectively reviewed. The main outcomes of interest were the bladder diary data and four urodynamic parameters: maximum cystometric capacity (MCC), maximum detrusor pressure (PDET max), and volume at first uninhibited detrusor contraction (UDC)...
April 21, 2017: Neurourology and Urodynamics
https://www.readbyqxmd.com/read/28388718/abobotulinumtoxina-a-25-year-history
#17
REVIEW
Gary D Monheit, Andy Pickett
During the late 1960s and early 1970s, Alan Scott showed that intramuscular injections of botulinum toxin (BoNT) corrected nonaccommodative strabismus without resorting to surgery. The UK doctors who trained with Scott soon realized the significant potential offered by BoNT type A as a therapeutic option for several difficult-to-treat diseases. This led to a collaboration between these pioneering clinicians and the Centre for Applied Microbiology and Research at Porton Down, United Kingdom, and, in turn, to the development and commercialization of abobotulinumtoxinA as Dysport (Dystonia/Porton Down; Ipsen Biopharm Ltd...
May 1, 2017: Aesthetic Surgery Journal
https://www.readbyqxmd.com/read/28388717/key-parameters-for-the-use-of-abobotulinumtoxina-in-aesthetics-onset-and-duration
#18
REVIEW
Mark Nestor, Glynis Ablon, Andy Pickett
Time to onset of response and duration of response are key measures of botulinum toxin efficacy that have a considerable influence on patient satisfaction with aesthetic treatment. However, there is no overall accepted definition of efficacy for aesthetic uses of botulinumtoxinA (BoNT-A). Mechanical methods of assessment do not lend themselves to clinical practice and clinicians rely instead on assessment scales such as the Frontalis Activity Measurement Standard, Frontalis Rating Scale, Wrinkle Severity Scale, and Subject Global Assessment Scale, but not all of these have been fully validated...
May 1, 2017: Aesthetic Surgery Journal
https://www.readbyqxmd.com/read/28388716/introduction-to-the-supplement-a-review-of-abobotulinumtoxina-dysport
#19
Jeffrey S Dover
No abstract text is available yet for this article.
May 1, 2017: Aesthetic Surgery Journal
https://www.readbyqxmd.com/read/28263010/bilateral-analgesic-effects-of-abobotulinumtoxina-dysport-%C3%A2-following-unilateral-administration-in-the-rat
#20
C Favre-Guilmard, P-E Chabrier, M Kalinichev
BACKGROUND: In addition to inhibition of muscle and glandular hyperactivity, botulinum neurotoxin (BoNT) type A also interferes with pain processing. Previously, in a rat model of paclitaxel-induced polyneuropathy, abobotulinumtoxinA (aboBoNT-A) elicited analgesic effects not only in the injected paw, but also in the contralateral, non-injected paw. METHODS: Here, we assessed bilateral analgesic effects of unilateral aboBoNT-A in several chronic pain models in Sprague-Dawley rats...
May 2017: European Journal of Pain: EJP
keyword
keyword
9455
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"